Ricks also pushes back on muscle loss worries, calling competitors' alarm absurd, and says only about 8 to 9% of eligible people use branded GLP-1s.
Recap by typeshit. Full story at BigGo Finance.
Keltie Knight shares a personal take on body image pressure on women, tagged with GLP-1 and BookTok. It's a short social clip with few specifics.
8:41
The weekly tirzepatide update marks a milestone for the channel, with the scale finally dipping below 220 pounds.
Dr. Salas-Whalen makes the case that stepping down on a GLP-1 dose can be as important as going up. Her view, not a protocol.
A short link post on what patients should keep in mind as options for semaglutide and tirzepatide keep shifting. Details are at the source.
Georgakis points out that omics work usually shows up in observational cohorts, and credits Novo for building it into trials and sharing the findings.
She cautions that just dropping to a lower dose and calling it maintenance may not be the right or safest way to come off the drug.
Loading…